<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report the experience from the <z:hpo ids='HP_0003613'>Antiphospholipid Antibodies</z:hpo> (aPL) Regional Consortium in northwest Italy, meant to support clinical research and foster collaboration among health professionals regarding the diagnosis and management of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) patients </plain></SENT>
<SENT sid="1" pm="."><plain>This cohort-study (APS Piedmont Cohort) was designed to register the clinical characteristics at inception and associated immunological manifestations at diagnosis (if any) of patients who strictly fulfilled the current criteria for APS, <z:hpo ids='HP_0000001'>all</z:hpo> recruited at the Piedmont and Valle d'Aosta regions </plain></SENT>
<SENT sid="2" pm="."><plain>Clinical and laboratory data from 217 APS patients (171 with vascular events, 33 with pregnancy morbidity and 13 with both), from 16 centres within the geographical area were collected </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0004936'>Venous thrombosis</z:hpo> was recorded in 45.6% of patients, <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> in 35%, small-vessel <z:mp ids='MP_0005048'>thrombosis</z:mp> in 1.12% and mixed arterial and <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> in the remaining 19.4% of the cases </plain></SENT>
<SENT sid="4" pm="."><plain>Pregnancy morbidity included 19 patients with unexplained fetal <z:hpo ids='HP_0011420'>death</z:hpo> beyond the 10th week of pregnancy, 17 with <z:hpo ids='HP_0001622'>premature birth</z:hpo> before the 34th week and 10 with three or more unexplained <z:hpo ids='HP_0005268'>spontaneous abortions</z:hpo> before the 10th week of gestation </plain></SENT>
<SENT sid="5" pm="."><plain>This consortium represents an instrument by which to audit clinical practice, to provide counselling to local centres and to sustain future basic and clinical APS research </plain></SENT>
</text></document>